About Us

We want to fundamentally change the way neurological and psychiatric conditions are treated.

Born out of the Beckley Foundation and underpinned by two decades of scientific research, we are combining world-leading psychedelic science, clinical drug development expertise and a pioneering approach to the use of digital tools in order to optimise patient outcomes, revolutionise treatment and ease the burden these conditions have on patients and society.

Due to our unique heritage and science-driven approach, we are able to work with some of the leading specialists in the world and we have established a global network of world-class physicians, scientists and thought leaders to assist us in our efforts to deliver innovative solutions where there is high unmet need.


For our founders, Lady Amanda Feilding and Cosmo Feilding Mellen, psychedelic medicines have been a lifelong and intergenerational vocation.

Amanda has dedicated over 50 years to the scientific exploration of psychedelics in the belief that modern science can be used to understand, validate, and optimise the healing potential of psychedelic medicines. In 1998 Amanda set up (and continues to run) the Beckley Foundation, a non-profit NGO focused on evidence-based drug policy reform and scientific research into psychedelic medicines.

Over the last 20 years the Beckley Foundation has become a world-famous pioneer in psychedelic research. Amanda has been dubbed “the hidden hand” behind the renaissance in psychedelic science, featured on the Guardian’s list of the Bravest Men and Women in the History of Science, and has personally co-authored over 50 peer-reviewed scientific publications on the subject, many with ground-breaking results.

Beckley Psytech was created to build upon the Foundation’s work by developing safe and effective psychedelic medicines for patients in need and integrating these treatments into mainstream medical practices.

Beckley Psytech has a close strategic partnership with the Beckley Foundation and, in addition to its own pipeline, will provide financial and technical support to develop the Foundation’s most promising research. The company is committed to improving the lives of patients in need and will donate a share of future revenues to fund the non-profit work of the Foundation.

Study on psychedelics and cerebral circulation
First Ethics Committee approval of LSD study since prohibition
Beckley-Imperial Psychedelic Research Programme
Global public letter for Drug Policy Reform
First ever brain imaging study on psilocybin
Psilocybin Tobacco Addiction Study
Psilocybin Treatment-Resistant Depression
Ayahuasca Neurogenesis study
LSD Microdosing study
Beckley Psytech Established
Initiation of 5-MeO-DMT Phase 1 (SAD) study in Healthy Volunteers
Submission and initiation of Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
First cohort of psychotherapists trained and certified for upcoming Phase 2 TRD trials
Initiation of 5-MeO-DMT Phase IIa TRD study
Received FDA's first ever IND approval for a Phase IIb study of a short-acting psychedelic
Initiation of 5-MeO-DMT Phase IIa AUD study